$SLSN

Solesence Received Notice of Noncompliance

Solesence (SLSN) received a notice from Nasdaq for failing to meet the $1.00 minimum bid price requirement. The company has 180 days to comply by achieving a $1.00 bid price for 10 consecutive days. The notice does not have an immediate effect.

Original reporting
Published Oct 2, 2026, 8:03 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Solesence Received Notice of Noncompliance — source image
Decision brief

The 30-second read

$SLSNBearishLow
01

Why it matters

The filing signals heightened regulatory risk for SLSN and may prompt short sellers.

02

Market read

The notice is a material corporate event that could affect SLSN's share price and investor sentiment.

03

What to watch

Potential for a reverse split or listing transfer that could mitigate delisting risk.

Relevance 6/10Novelty 7/10Timing: pre‑market today

Background

Nasdaq Listing Rule 5550(a)(2) requires a $1.00 minimum bid price; non‑compliance triggers a delisting review.

Company-level read

Ticker impact

$SLSNBearishHigh confidence
Context

Nasdaq notice of non‑compliance with $1.00 minimum bid price after 30 days below $1.00.

Expected impact

likely pressure as the market prices in the compliance risk

Evidence & confidence

The 180‑day cure window and prior price weakness suggest investors may sell or avoid the stock.

Market effects

May raise scrutiny on other low‑price microcaps on Nasdaq.

Limited to U.S. listed micro‑cap segment.

Minimal global impact.

Counterpoint

If the company secures a capital raise quickly, the notice could be a short‑term catalyst.

Key entities

  • Solesence Inc.

    Micro‑cap listed on Nasdaq under ticker SLSN.

  • Nasdaq

    Regulatory body issuing the non‑compliance notice.

Related articles

$SLSNMed

Solésence Reports Second Quarter 2026 Financial Results

SOLESENCE, INC. (SLSN) filed an SEC Form 8-K — Results of Operations and Financial Condition. EXHIBIT 99.1 Solésence Reports Second Quarter 2026 Financial Results Quarterly Report Filed on Form 10-Q Company to Host Conference Call at 5:00 p.m. ET Today ROMEOVILLE, Ill., Aug. 19, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically driven hea

$ABBVMed

AbbVie, Amgen, Pfizer, GSK among participants in new 340B rebate pilot

The Trump administration selected 10 drugmakers, including AbbVie, Amgen, Pfizer, and GSK, for a 340B rebate pilot program starting January 1. The program tests a rebate model for 21 discounted drugs under the 340B program. The HRSA oversees the initiative, aiming to address compliance proactively. The program is contentious, with pharmaceutical companies and hospitals disputing its impact.

$BLKMedAI 8/10

BlackRock Bitcoin ETF Flashes Golden Cross As SEC Approves Triple-Leveraged Bitcoin, Ethereum ETPs

BlackRock's iShares Bitcoin Trust ETF (IBIT) showed a golden cross, with its 50-day SMA crossing above the 200-day SMA. The SEC approved a rule change for triple-leveraged Bitcoin and Ethereum ETPs. IBIT had $195.57 million in inflows on Oct. 1, contributing to $102.67 million in total net inflows for US spot Bitcoin ETFs. The SEC's approval allows Volatility Shares to list six leveraged products, including Bitcoin and Ethereum funds.

$GOOGLLow

American Airlines Pilots Urge Court To Block Google Buying Spirit Crews' Confidential Data

American Airlines Pilots Association (APA) urged a court to block Google's $10M purchase of Spirit Airlines' corporate records, citing concerns over confidentiality of pilots' safety and training data. APA argues the deal could deter pilots from reporting safety issues. Other unions and EPIC also oppose the sale, citing risks of deidentification and data monetization. The court has not yet approved the purchase.

$LLYHigh

FDA Approves Expanded Use Of Lilly's Jaypirca For CLL/SLL

Eli Lilly (LLY) announced FDA approval for Jaypirca (pirtobrutinib) as a first-line treatment for adults with CLL/SLL without 17p deletion. The drug is the first FDA-approved non-covalent BTK inhibitor. LLY continues Phase 3 studies for further expansion. LLY stock closed at $1,142.85, down 0.61%.